A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus
Latest Information Update: 08 Dec 2021
At a glance
- Drugs Liraglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Novo Nordisk
Most Recent Events
- 16 Nov 2017 Status changed from active, no longer recruiting to completed.
- 13 Sep 2016 Status changed from recruiting to active, no longer recruiting.
- 28 Jul 2015 Status changed from not yet recruiting to recruiting as per ClinicalTrials.gov record.